Ichor Biologics

Ichor Biologics is a private, preclinical-stage biotech founded in 2015, leveraging a unique platform that identifies protective human immune responses to infectious diseases to develop antibody therapeutics. The company's core technology integrates immunology assays, antigen presentation methods, and machine learning to discover and optimize antibodies, with initial validation in hantavirus. Ichor's strategy involves advancing programs to preclinical proof-of-concept to generate intellectual property for potential partnerships or licensing deals with larger industry players.

Proprietary high-throughput platform for isolating naturally occurring human monoclonal antibodies. It integrates immunology assays to identify protective immune signatures, novel antigen presentation methods, and machine learning software for antibody characterization and optimization.

Ichor competes in the broad monoclonal antibody space against large pharmaceutical companies and biotechs. For hantavirus specifically, direct competition appears limited, but for platform applicability to other diseases, it faces competition from companies with similar antibody discovery technologies.